Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$12.81
+0.5%
$10.86
$6.55
$12.90
$1.68B1.261.48 million shs1.18 million shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$66.91
+2.0%
$61.64
$10.14
$69.36
$1.66B1.29436,801 shs1.18 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$27.18
-1.2%
$24.30
$10.81
$30.23
$398.64M0.31108,302 shs80,569 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$39.53
-0.2%
$32.18
$16.16
$41.57
$1.61B0.88385,401 shs365,189 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.00%+2.74%+3.83%+56.51%+81.22%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%+3.88%+0.63%+192.82%+449.58%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%-2.34%+17.96%+88.24%+67.70%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%+0.43%+29.18%+60.34%+80.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$12.81
+0.5%
$10.86
$6.55
$12.90
$1.68B1.261.48 million shs1.18 million shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$66.91
+2.0%
$61.64
$10.14
$69.36
$1.66B1.29436,801 shs1.18 million shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$27.18
-1.2%
$24.30
$10.81
$30.23
$398.64M0.31108,302 shs80,569 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$39.53
-0.2%
$32.18
$16.16
$41.57
$1.61B0.88385,401 shs365,189 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.00%+2.74%+3.83%+56.51%+81.22%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
0.00%+3.88%+0.63%+192.82%+449.58%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
0.00%-2.34%+17.96%+88.24%+67.70%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%+0.43%+29.18%+60.34%+80.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$12.00-6.32% Downside
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.11
Buy$64.14-4.14% Downside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.00
HoldN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.86
Reduce$28.40-28.16% Downside

Current Analyst Ratings Breakdown

Latest INBX, AUPH, CDTX, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$19.00 ➝ $27.00
8/28/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$34.00
8/28/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/22/2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$59.00 ➝ $66.00
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$53.00 ➝ $74.00
8/8/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$54.00 ➝ $74.00
8/1/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$8.00 ➝ $9.00
7/30/2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$17.00
7/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$69.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M7.17$0.31 per share41.31$2.68 per share4.78
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$1.27M1,336.09N/AN/A$14.92 per share4.48
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$200K1,967.83$113.25 per share0.24$9.23 per share2.94
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.24$3.26 per share12.12$7.05 per share5.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.4329.7922.88N/A23.31%20.06%13.81%11/6/2025 (Estimated)
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$11.13N/AN/AN/AN/A-50.81%-42.46%11/6/2025 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$1.1833.5018.821.183.73%32.14%6.89%11/5/2025 (Estimated)

Latest INBX, AUPH, CDTX, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.57+$0.05$0.42$362.24 million$378.70 million
8/13/2025Q2 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.92-$1.85+$1.07-$1.85N/A$1.30 million
8/7/2025Q2 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$1.87-$1.65+$0.22-$1.65N/AN/A
7/31/2025Q2 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.17$0.16-$0.01$0.16$64.27 million$70.01 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.21%N/A40.68%N/A

Latest INBX, AUPH, CDTX, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.26%9/3/20259/3/20259/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.18
5.23
4.63
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
16.45
16.45
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
1.45
4.98
4.98
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.46
2.76
1.25

Institutional Ownership

CompanyInstitutional Ownership
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300131.63 million115.57 millionOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9025.36 million23.42 millionNo Data
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.48 millionN/AOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.53 million20.24 millionOptionable

Recent News About These Companies

What is Zacks Research's Estimate for PAHC Q1 Earnings?
Zacks Research Analysts Boost Earnings Estimates for PAHC
Zacks Research Brokers Increase Earnings Estimates for PAHC
Zacks Research Has Optimistic Outlook of PAHC Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$12.81 +0.07 (+0.55%)
Closing price 04:00 PM Eastern
Extended Trading
$12.66 -0.15 (-1.13%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$66.91 +1.29 (+1.97%)
Closing price 04:00 PM Eastern
Extended Trading
$67.48 +0.58 (+0.86%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$27.18 -0.34 (-1.24%)
Closing price 04:00 PM Eastern
Extended Trading
$27.12 -0.07 (-0.24%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$39.53 -0.09 (-0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$40.04 +0.51 (+1.29%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.